Michael B. Cross
Corporate Officer/Principal presso SATELLOS BIOSCIENCE INC.
Profilo
Michael B.
Cross is the founder of ARTMS, Inc. He currently holds director positions at AdipoGenix, Inc., Aegera Therapeutics, Inc., Praxim SA, and Satellos Bioscience, Inc. In the past, he served as a director at Agrisoma Biosciences, Inc., Trillium Therapeutics, Inc., Viron Therapeutics, Inc., and Nordion (Canada), Inc. He was also the Chief Business Officer at OncoSec Medical, Inc. Additionally, he held positions at Lumira Capital Investment Management, Inc., Fairway Capital Management Corp., TraumaTec, Inc., and the Canada Department of National Defence (Canada).
Dr. Cross obtained an MBA and a doctorate from the University of Toronto.
Posizioni attive di Michael B. Cross
Società | Posizione | Inizio |
---|---|---|
SATELLOS BIOSCIENCE INC. | Corporate Officer/Principal | - |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Director/Board Member | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Director/Board Member | 24/09/2009 |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | Director/Board Member | 22/10/2009 |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | Founder | - |
Precedenti posizioni note di Michael B. Cross
Società | Posizione | Fine |
---|---|---|
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director/Board Member | - |
ONCOSEC MEDICAL INCORPORATED | Chief Operating Officer | 12/03/2012 |
Fairway Capital Management Corp. | Corporate Officer/Principal | 04/09/2008 |
NORDION INC | Corporate Officer/Principal | 01/01/2003 |
░░░░░░ ░░░░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formazione di Michael B. Cross
University of Toronto | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
ONCOSEC MEDICAL INCORPORATED | Health Services |
SATELLOS BIOSCIENCE INC. | Health Technology |
Aziende private | 12 |
---|---|
Nordion (Canada), Inc.
Nordion (Canada), Inc. Pharmaceuticals: MajorHealth Technology Nordion (Canada), Inc. provides drug discovery and development research services. It specializes in health science, gamma irradiation, radiopharmaceutical, gamma sterilization, medical isotopes, and production irradiators. The company was founded in 1946 and is headquartered in Ottawa, Canada. | Health Technology |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology AdipoGenix, Inc. develops molecular pharmaceutical products. It offers small molecule pharmaceuticals to treat obesity and its co-morbidities. The firm’s technology includes AdipoBASE, AdipoSCREEN, AdipoPATH and AdipoTARGET. The company was founded by Gerri Waloga, Barbara E. Corkey, Stephen R. Farmer, James A. Hamilton, James L. Kirkland, H. Jeff Leighton and Paul F. Pilch in 1997 and is headquartered in Boston, MA. | Health Technology |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
Fairway Capital Management Corp. | Finance |
Agrisoma Biosciences, Inc.
Agrisoma Biosciences, Inc. Chemicals: SpecialtyProcess Industries Agrisoma Biosciences, Inc. provides crop technology for biofuel and renewable energy solutions. Its crop improvement technologies include proprietary breeding, proprietary tissue culture and haploidy, molecular markers and genetic mapping and advanced crop improvement technologies. The company was founded by Steven Fabijanski and Tom Mamic in 2001 and is headquartered in Gatineau, Canada. | Process Industries |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Praxim SA
Praxim SA Medical SpecialtiesHealth Technology Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France. | Health Technology |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
TraumaTec, Inc.
TraumaTec, Inc. Electronic Equipment/InstrumentsElectronic Technology TraumaTec, Inc. manufactures medical devices. It develops patented, non-invasive, and disposable medical device that specifically targets cooling the brain to mitigate brain injury. The company was founded on March 25, 2003 and is headquartered in Houston, TX. | Electronic Technology |
Canada Department of National Defence (Canada) | Government |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada. | Health Technology |
- Borsa valori
- Insiders
- Michael B. Cross